State Street Corp Reduces Position in Agilent Technologies, Inc. $A

State Street Corp decreased its holdings in Agilent Technologies, Inc. (NYSE:A) by 1.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,453,528 shares of the medical research company’s stock after selling 155,764 shares during the period. State Street Corp’s holdings in Agilent Technologies were worth $1,469,641,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC grew its stake in Agilent Technologies by 6.1% in the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock valued at $626,000 after buying an additional 270 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new stake in shares of Agilent Technologies during the first quarter worth $210,000. Zions Bancorporation National Association UT bought a new position in shares of Agilent Technologies in the first quarter worth $38,000. Townsquare Capital LLC grew its position in shares of Agilent Technologies by 33.2% in the first quarter. Townsquare Capital LLC now owns 3,453 shares of the medical research company’s stock valued at $404,000 after purchasing an additional 860 shares in the last quarter. Finally, Invesco Ltd. grew its position in shares of Agilent Technologies by 8.5% in the first quarter. Invesco Ltd. now owns 2,287,302 shares of the medical research company’s stock valued at $267,569,000 after purchasing an additional 179,101 shares in the last quarter.

Agilent Technologies Stock Performance

Shares of A opened at $143.51 on Thursday. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $160.27. The company has a current ratio of 1.96, a quick ratio of 1.52 and a debt-to-equity ratio of 0.45. The company has a market cap of $40.68 billion, a PE ratio of 31.40, a price-to-earnings-growth ratio of 4.08 and a beta of 1.27. The stock has a 50-day moving average price of $145.55 and a 200-day moving average price of $128.71.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Monday, November 24th. The medical research company reported $1.59 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.01. The company had revenue of $1.86 billion for the quarter, compared to analysts’ expectations of $1.83 billion. Agilent Technologies had a net margin of 18.75% and a return on equity of 25.20%. During the same period in the prior year, the business earned $1.46 earnings per share. Agilent Technologies’s revenue for the quarter was up 9.4% compared to the same quarter last year. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. As a group, equities analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 28th. Stockholders of record on Tuesday, January 6th will be given a dividend of $0.255 per share. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.25. The ex-dividend date is Tuesday, January 6th. This represents a $1.02 annualized dividend and a dividend yield of 0.7%. Agilent Technologies’s dividend payout ratio is 21.66%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on A shares. The Goldman Sachs Group began coverage on Agilent Technologies in a report on Tuesday. They set a “buy” rating and a $170.00 price objective on the stock. Barclays upped their price target on Agilent Technologies from $145.00 to $165.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 25th. Wall Street Zen upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. TD Cowen boosted their price objective on shares of Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Finally, Rothschild & Co Redburn assumed coverage on shares of Agilent Technologies in a research note on Wednesday, October 8th. They issued a “buy” rating and a $165.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $161.77.

Insiders Place Their Bets

In related news, VP Rodney Gonsalves sold 3,000 shares of the company’s stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $154.99, for a total value of $464,970.00. Following the completion of the transaction, the vice president directly owned 31,846 shares in the company, valued at approximately $4,935,811.54. The trade was a 8.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Padraig Mcdonnell sold 911 shares of the stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $143.24, for a total value of $130,491.64. Following the completion of the transaction, the chief executive officer directly owned 32,058 shares in the company, valued at approximately $4,591,987.92. This represents a 2.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 16,401 shares of company stock valued at $2,468,962 over the last ninety days.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.